Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.64 USD | -2.89% | -7.31% | -27.35% |
Apr. 09 | UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating | MT |
Apr. 03 | Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.35% | 2.3B | |
-1.49% | 105B | |
+3.57% | 97.5B | |
+1.86% | 22.19B | |
-16.70% | 21.33B | |
-8.49% | 18.68B | |
-42.33% | 16.6B | |
-20.40% | 14.52B | |
+5.57% | 14.09B | |
+28.97% | 10.99B |
- Stock Market
- Equities
- DNLI Stock
- News Denali Therapeutics Inc.
- Denali Therapeutics : Wedbush Adjusts Price Target on Denali Therapeutics to $90 From $64 on Cash Outlook, Pipeline Valuation; Outperform Rating Kept